[Lupus nephritis, mycophenolate, and cytomegalovirus infection].
Sánchez de la Nieta
M D
MD
Carreño
A
A
de la Torre
M
M
Rivera
F
F
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D003520:Cyclophosphamide / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000150:complications*; D004198:Disease Susceptibility; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007075:Immunoglobulin M / Q000097:blood; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008181:Lupus Nephritis / Q000150:complications* / Q000188:drug therapy; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use
D000914:Antibodies, Viral; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003520:Cyclophosphamide; D009173:Mycophenolic Acid; D011241:Prednisone